Printer Friendly
The Free Library
19,604,530 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Array BioPharma To Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2004 on August 2, 2004.


BOULDER Boulder, city, United States
Boulder, city (1990 pop. 83,312), seat of Boulder co., N central Colo.; inc. 1871. A Rocky Mountain resort and a suburb of Denver, it is the seat of the Univ. of Colorado (1876).
, Colo. -- Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the fourth quarter and full year of fiscal 2004 on Monday, August 2, 2004, at 4:30 p.m. eastern time and hold a conference call on Tuesday, August 3, 2004, at 9:00 a.m. eastern time. Robert E. Conway, Chief Executive Officer, and Michael Carruthers, Chief Financial Officer, will lead the call.
CONFERENCE CALL INFORMATION
Date:        Tuesday, August 3, 2004
Time:        9:00 a.m. eastern time
Toll-Free:   (800) 946-0719
Toll:        (719) 457-2645
Pass Code:   661325
Web Cast:    www.arraybiopharma.com


There will be a replay of the conference call for one week, which can be accessed in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area.  by dialing toll-free (888) 203-1112, and outside the United States (719) 457-0820. The access code is 661325. Replay of the call will also be available as a web cast on Array's web site at www.arraybiopharma.com.

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of orally active drugs to address significant unmet un·met  
adj.
Not satisfied or fulfilled: unmet demands. 
 medical needs. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease Noun 1. inflammatory disease - a disease characterized by inflammation
disease - an impairment of health or a condition of abnormal functioning

NEC, necrotizing enterocolitis - an acute inflammatory disease occurring in the intestines of premature infants;
 and includes several small molecule drug candidates that are designed to regulate targets in therapeutically important biologic pathways. In addition, leading pharmaceutical and biotechnology companies Top 100 Biotechnology Companies
The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies.
 access our drug discovery technologies and expertise through collaborations to design, create, optimize optimize - optimisation  and evaluate drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 28, 2004
Words:251
Previous Article:Jobing.com Expands Operations in Rhode Island; Leading Local Job Board Provider to Increase Operations Throughout Southern New England.
Next Article:Timberland Bancorp, Inc. Announces Increased Third Quarter Earnings and Increased Dividend.



Related Articles
Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2002 On August 5, 2002.
Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2003 On August 4, 2003.
Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2004 on November 3, 2003.
Array BioPharma To Report Financial Results for the Second Quarter of Fiscal 2004 on February 2, 2004.
Array BioPharma To Report Financial Results for the Third Quarter of Fiscal 2004 on May 3, 2004.
Dollar Financial Group, Inc. Issues Updated Estimate for Fiscal Fourth Quarter and Fiscal Year Ended June 30, 2004.
Jabil Circuit Reports Fourth Quarter & Fiscal Year 2004 Results; Company Posts Record Revenues for Quarter and Year.
Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2005 On November 1, 2004.
CBRL Group, Inc. Announces Increase in Diluted Net Income Per Share for Fiscal 2005 Fourth Quarter; Announces Results for Full Year of Fiscal 2005.
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2007.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles